337 related articles for article (PubMed ID: 15082596)
41. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study.
Alexander J; Torbenson M; Wu TT; Yeh MM
J Gastroenterol Hepatol; 2013 May; 28(5):848-54. PubMed ID: 23302015
[TBL] [Abstract][Full Text] [Related]
42. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality.
Younossi Z; Henry L
Gastroenterology; 2016 Jun; 150(8):1778-85. PubMed ID: 26980624
[TBL] [Abstract][Full Text] [Related]
43. Histological assessment of non-alcoholic fatty liver disease.
Hübscher SG
Histopathology; 2006 Nov; 49(5):450-65. PubMed ID: 17064291
[TBL] [Abstract][Full Text] [Related]
44. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease.
Bhagat V; Mindikoglu AL; Nudo CG; Schiff ER; Tzakis A; Regev A
Liver Transpl; 2009 Dec; 15(12):1814-20. PubMed ID: 19938128
[TBL] [Abstract][Full Text] [Related]
45. Morphometry of liver parenchyma in needle biopsy specimens from patients with alcoholic liver disease: preliminary variables for the diagnosis and prognosis of cirrhosis.
Ryoo JW; Buschmann RJ
Mod Pathol; 1989 Jul; 2(4):382-9. PubMed ID: 2668943
[TBL] [Abstract][Full Text] [Related]
46. Silent non-alcoholic fatty liver disease-a clinical-histological study.
Sorrentino P; Tarantino G; Conca P; Perrella A; Terracciano ML; Vecchione R; Gargiulo G; Gennarelli N; Lobello R
J Hepatol; 2004 Nov; 41(5):751-7. PubMed ID: 15519647
[TBL] [Abstract][Full Text] [Related]
47. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age- and body mass index-matched cohorts.
Hashizume H; Sato K; Yamazaki Y; Horiguchi N; Kakizaki S; Mori M
Acta Med Okayama; 2013; 67(1):45-53. PubMed ID: 23439508
[TBL] [Abstract][Full Text] [Related]
48. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
49. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management.
Siddiqui MS; Charlton M
Gastroenterology; 2016 Jun; 150(8):1849-62. PubMed ID: 26971826
[TBL] [Abstract][Full Text] [Related]
50. [Stellate reticuloendotheliocytes in cirrhosis of the liver].
Aruin LI; Loginov AS; Shatalova OL
Arkh Patol; 1987; 49(3):31-7. PubMed ID: 3593004
[TBL] [Abstract][Full Text] [Related]
51. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis.
Tsang SW; Ng WF; Wu BP; Chow DA; Li ET; Wong TC
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):116-21. PubMed ID: 16706822
[TBL] [Abstract][Full Text] [Related]
52. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.
Park GJ; Wiseman E; George J; Katelaris PH; Seow F; Fung C; Ngu MC
J Gastroenterol Hepatol; 2011 Sep; 26(9):1411-6. PubMed ID: 21557768
[TBL] [Abstract][Full Text] [Related]
53. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
[TBL] [Abstract][Full Text] [Related]
54. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.
Dyson JK; McPherson S; Anstee QM
Postgrad Med J; 2014 May; 90(1063):254-66. PubMed ID: 24737902
[TBL] [Abstract][Full Text] [Related]
55. Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study.
Askgaard G; Leon DA; Kjaer MS; Deleuran T; Gerds TA; Tolstrup JS
Hepatology; 2017 Mar; 65(3):929-937. PubMed ID: 27862159
[TBL] [Abstract][Full Text] [Related]
56. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
57. Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease.
Masson S; Emmerson I; Henderson E; Fletcher EH; Burt AD; Day CP; Stewart SF
Liver Int; 2014 Feb; 34(2):235-42. PubMed ID: 23834275
[TBL] [Abstract][Full Text] [Related]
58. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
[TBL] [Abstract][Full Text] [Related]
59. Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy.
Myers RP; Crotty P; Pomier-Layrargues G; Ma M; Urbanski SJ; Elkashab M
Liver Int; 2010 Nov; 30(10):1471-80. PubMed ID: 20807336
[TBL] [Abstract][Full Text] [Related]
60. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
Williams KH; Vieira De Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Brooks B; Bu Y; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Keane FM; Zekry A; Gorrell MD; Twigg SM
J Diabetes; 2015 Nov; 7(6):809-19. PubMed ID: 25350950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
